Manuscripts and Publications

Filters: Author is Peters, Stephen P  [Clear All Filters]
2022
Krishnan JK, Ancy KM, Oromendia C, Hoffman KL, Easthausen I, Leidy NK, Han MK, Bowler RP, Christenson SA, Couper DJ et al..  2022.  Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Instrument. Chronic Obstr Pulm Dis. 9(2):195-208.
O'Toole J, Woo H, Putcha N, Cooper CB, Woodruff P, Kanner RE, Paine R, Bowler RP, Comellas A, Hoth KF et al..  2022.  Comparative Impact of Depressive Symptoms and FEV% on Chronic Obstructive Pulmonary Disease.. Ann Am Thorac Soc. 19(2):171-178.
Ronish BE, Couper DJ, Barjaktarevic IZ, Cooper CB, Kanner RE, Pirozzi CS, Kim V, Wells JM, Han MK, Woodruff PG et al..  2022.  Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort.. Chronic Obstr Pulm Dis. 9(2):111-121.
Madapoosi SS, Cruickshank-Quinn C, Opron K, Erb-Downward JR, Begley LA, Li G, Barjaktarevic I, R Barr G, Comellas AP, Couper DJ et al..  2022.  Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease.. Am J Respir Crit Care Med. 206(4):427-439.
Godbole S, Labaki WW, Pratte KA, Hill A, Moll M, Hastie AT, Peters SP, Gregory A, Ortega VE, Demeo D et al..  2022.  A Metabolomic Severity Score for Airflow Obstruction and Emphysema.. Metabolites. 12(5)
Baugh A, Buhr RG, Quibrera P, Barjaktarevic I, R Barr G, Bowler R, Han MKing, Kaufman JD, Koch AL, Krishnan J et al..  2022.  Risk of COPD exacerbation is increased by poor sleep quality and modified by social adversity.. Sleep. 45(8)
2020
Zhang WZ, Rice MC, Hoffman KL, Oromendia C, Barjaktarevic IZ, J Wells M, Hastie AT, Labaki WW, Cooper CB, Comellas AP et al..  2020.  Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort. JCI Insight. 5(3)
Ortega VE, Li X, O'Neal WK, Lackey L, Ampleford E, Hawkins GA, Grayeski PJ, Laederach A, Barjaktarevic I, R Barr G et al..  2020.  The Effects of Rare Variants on Lung Function and Emphysema in SPIROMICS.. Am J Respir Crit Care Med. 201(5):540-554.
Zhang WZ, Oromendia C, Kikkers SAnn, Butler JJ, O'Beirne S, Kim K, O'Neal WK, Freeman CM, Christenson SA, Peters SP et al..  2020.  Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS.. Sci Rep. 10(1):10562.
Cooper CB, Paine R, Curtis JL, Kanner RE, Martinez CH, Meldrum CA, Bowler R, O'Neal W, Hoffman EA, Couper D et al..  2020.  Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort.. Int J Chron Obstruct Pulmon Dis. 15:1887-1898.
Burkes RM, Ceppe AS, Couper DJ, Comellas AP, J Wells M, Peters SP, Criner GJ, Kanner RE, Paine R, Christenson SA et al..  2020.  Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.. Chronic Obstr Pulm Dis. 7(4):370-381.
Strand M, Austin E, Moll M, Pratte KA, Regan EA, Hayden LP, Bhatt SP, Boriek AM, Casaburi R, Silverman EK et al..  2020.  A Risk Prediction Model for Mortality Among Smokers in the COPDGene® Study.. Chronic Obstr Pulm Dis. 7(4):346-361.
2019
Ghosh S, Anderson WH, Putcha N, Han MK, Curtis JL, Criner GJ, Dransfield MT, R Barr G, Krishnan JA, Lazarus SC et al..  2019.  Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS.. Ann Am Thorac Soc. 16(2):200-208.
Fawzy A, Putcha N, Aaron CP, Bowler RP, Comellas AP, Cooper CB, Dransfield MT, Han MK, Hoffman EA, Kanner RE et al..  2019.  Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score-Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study.. Chest. 155(3):519-527.
Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Iii RPaine, Bhatt SP, Bhakta NR et al..  2019.  Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.. Int J Chron Obstruct Pulmon Dis. 14:2927-2938.
Arjomandi M, Zeng S, Barjaktarevic I, R Barr G, Bleecker ER, Bowler RP, Buhr RG, Criner GJ, Comellas AP, Cooper CB et al..  2019.  Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS.. Eur Respir J. 54(4)
Labaki WW, Gu T, Murray S, Curtis JL, Yeomans L, Bowler RP, R Barr G, Comellas AP, Hansel NN, Cooper CB et al..  2019.  Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study.. Sci Rep. 9(1):11367.
Garudadri S, Woodruff PG, Han MK, Curtis JL, R Barr G, Bleecker ER, Bowler RP, Comellas A, Cooper CB, Criner G et al..  2019.  Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS.. Chest. 155(5):908-917.

Pages